Takis Athanasopoulos

Dr Takis Athanasopoulos is currently appointed as VP of Gene Therapy Research & Vector Technology, at Vigeneron GmBH, Munich, Germany. Prior to joining ViGeneron, Takis previously held leadership positions at GSK (Sep 2016-Mar 2023). For 6.5 years he has acted as Director & Head of various functional CGT GSK units i.e.Vector Innovation/Vector Development, Patient Operations, Transgene Delivery and Vector & Transgene Units, as part of Cell & Gene Therapy (CGT), Medicinal Science & Technology (MST) platform of GSK at Stevenage, UK. Before joining GSK, Takis was a Lecturer in Molecular Biotechnology at the University of Wolverhampton (September 2011-2016), Founder and CEO of Gene & Cell Ltd. and Academic Visitor/Research Consultant for the Gene Therapy Group at Royal Holloway University of London.  Takis has worked previously, as a research staff scientist/PDRA in the School of Biological Sciences at Royal Holloway, University of London (RHUL). He has also worked on collaborative projects with scientists/clinicians at Royal Free Hospital/UCL and Imperial College London (ICL) and he has been previously funded by the State Scholarship Foundation SF/IKY (Greece), Muscular Dystrophy Campaign (UK), and by the Collaboration for AIDS Vaccine Discovery (CAVD) and the Bill & Melinda Gates Foundation (BMGF).